<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36360172</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1935</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes13111935</ELocationID><Abstract><AbstractText>The aim of the study was to identify the association between four selected COVID-19 polymorphisms of ACE2 and TMPRSS2 receptors genes with the presence of long-COVID symptomatology in COVID-19 survivors. These genes were selected as they associate with the entry of the SARS-CoV-2 virus into the cells, so polymorphisms could be important for the prognoses of long-COVID symptoms. Two hundred and ninety-three (n = 293, 49.5% female, mean age: 55.6 &#xb1; 12.9 years) individuals who had been previously hospitalized due to COVID-19 were included. Three potential genotypes of the following single nucleotide polymorphisms (SNPs) were obtained from non-stimulated saliva samples of participants: ACE2 (rs2285666), ACE2 (rs2074192), TMPRSS2 (rs12329760), TMPRSS2 (rs2070788). Participants were asked to self-report the presence of any post-COVID defined as a symptom that started no later than one month after SARS-CoV-2 acute infection and whether the symptom persisted at the time of the study. At the time of the study (mean: 17.8, SD: 5.2 months after hospital discharge), 87.7% patients reported at least one symptom. Fatigue (62.8%), pain (39.9%) or memory loss (32.1%) were the most prevalent post-COVID symptoms. Overall, no differences in long-COVID symptoms were dependent on ACE2 rs2285666, ACE2 rs2074192, TMPRSS2 rs12329760, or TMPRSS2 rs2070788 genotypes. The four SNPs assessed, albeit previously associated with COVID-19 severity, do not predispose for developing long-COVID symptoms in people who were previously hospitalized due to COVID-19 during the first wave of the pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3772-9690</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, 28922 Alcorc&#xf3;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arendt-Nielsen</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Gastroenterology, Mech-Sense, Aalborg University Hospital, DK-9000 Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Gil</LastName><ForeName>Gema</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3480-1490</Identifier><AffiliationInfo><Affiliation>Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Alcorc&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Esquer</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5426-4349</Identifier><AffiliationInfo><Affiliation>Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Alcorc&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Crujera</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1022-5831</Identifier><AffiliationInfo><Affiliation>Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Alcorc&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-S&#xe1;nchez</LastName><ForeName>Stella M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-7140-4286</Identifier><AffiliationInfo><Affiliation>Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Alcorc&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambite-Quesada</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6755-8189</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Universidad Rey Juan Carlos, 28922 Alcorc&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palomar-Gallego</LastName><ForeName>Mar&#xed;a A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-4018-2270</Identifier><AffiliationInfo><Affiliation>Research Group GAMDES, Department of Basic Health Sciences, Universidad Rey Juan Carlos (URJC), 28922 Alcorc&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellicer-Valero</LastName><ForeName>Oscar J</ForeName><Initials>OJ</Initials><Identifier Source="ORCID">0000-0002-0104-1029</Identifier><AffiliationInfo><Affiliation>Intelligent Data Analysis Laboratory, Department of Electronic Engineering, ETSE (Engineering School), Universitat de Val&#xe8;ncia, 46100 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giordano</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1331-129X</Identifier><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C421305">TMPRSS2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">TMPRSS2</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">post-COVID</Keyword><Keyword MajorTopicYN="N">single nucleotide polymorphism</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36360172</ArticleId><ArticleId IdType="pmc">PMC9690177</ArticleId><ArticleId IdType="doi">10.3390/genes13111935</ArticleId><ArticleId IdType="pii">genes13111935</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Christie M.J., Irving A.T., Forster S.C., Marsland B.J., Hansbro P.M., Hertzog P.J., Nold-Petry C.A., Nold M.F. Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci. Immunol. 2021;6:205. doi: 10.1126/sciimmunol.abd0205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd0205</ArticleId><ArticleId IdType="pubmed">34533977</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H.O., Choudhari R., Nema V., Khan A.A. ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. Microb. Pathog. 2021;150:104621. doi: 10.1016/j.micpath.2020.104621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104621</ArticleId><ArticleId IdType="pmc">PMC7709597</ArticleId><ArticleId IdType="pubmed">33278516</ArticleId></ArticleIdList></Reference><Reference><Citation>Glotov O.S., Chernov A.N., Scherbak S.G., Baranov V.S. Genetic risk factors for the development of COVID-19 coronavirus infection. Russ. J. Genet. 2021;57:878&#x2013;892. doi: 10.1134/S1022795421080056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S1022795421080056</ArticleId><ArticleId IdType="pmc">PMC8404752</ArticleId><ArticleId IdType="pubmed">34483599</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A., Bandopadhyay A., Das D., Pandey R.K., Singh V., Khanam N., Srivastava N., Singh P.P., Dubey P.K., Pathak A., et al. Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India. Front. Genet. 2020;11:564741. doi: 10.3389/fgene.2020.564741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.564741</ArticleId><ArticleId IdType="pmc">PMC7545580</ArticleId><ArticleId IdType="pubmed">33101387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikanth V., Sasikala M., Naveen V., Latha S.S., Parsa K.V.L., Vijayasarathy K., Amanchy R., Avanthi S., Govardhan B., Rakesh K., et al. A variant in TMPRSS2 is associated with decreased disease severity in COVID-19. Meta Gene. 2021;29:100930. doi: 10.1016/j.mgene.2021.100930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mgene.2021.100930</ArticleId><ArticleId IdType="pmc">PMC8161869</ArticleId><ArticleId IdType="pubmed">34075330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y., Zhao J., Martin W., Kallianpur A., Chung M.K., Jehi L., Sharifi N., Erzurum S., Eng C., Cheng F. New insights into genetic susceptibility of COVID-19: An ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020;18:216. doi: 10.1186/s12916-020-01673-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01673-z</ArticleId><ArticleId IdType="pmc">PMC7360473</ArticleId><ArticleId IdType="pubmed">32664879</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrijevic Z., Robajac D., Gligorijevic N., &#x160;underic M., Penezic A., Milju&#x161; G., Nedic O. The association of ACE1, ACE2, TMPRSS2, IFITM3 and VDR polymorphisms with COVID-19 severity: A systematic review and meta-analysis. EXCLI J. 2022;21:818&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9360474</ArticleId><ArticleId IdType="pubmed">35949487</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K., Kaur G., Pathak T., Banerjee I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 2022;844:146790. doi: 10.1016/j.gene.2022.146790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2022.146790</ArticleId><ArticleId IdType="pmc">PMC9384365</ArticleId><ArticleId IdType="pubmed">35987511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-G&#xf3;mez L.E., Herrera-L&#xf3;pez B., Martinez-Armenta C., Ortega-Pe&#xf1;a S., Camacho-Rea M.D.C., Suarez-Ahedo C., V&#xe1;zquez-C&#xe1;rdenas P., Vargas-Alarc&#xf3;n G., Rojas-Velasco G., Fragoso J.M., et al. ACE and ACE2 gene variants are associated with severe outcomes of COVID-19 in men. Front. Immunol. 2022;13:812940. doi: 10.3389/fimmu.2022.812940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.812940</ArticleId><ArticleId IdType="pmc">PMC8892378</ArticleId><ArticleId IdType="pubmed">35250987</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulandari L., Hamidah B., Pakpahan C., Damayanti N.S., Kurniati N.D., Adiatmaja C.O., Wigianita M.R., Soedarsono Husada D., Tinduh D., Prakoeswa C.R.S., et al. Initial study on TMPRSS2 p. Val160Met genetic variant in COVID-19 patients. Hum. Genom. 2021;15:29. doi: 10.1186/s40246-021-00330-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40246-021-00330-7</ArticleId><ArticleId IdType="pmc">PMC8127183</ArticleId><ArticleId IdType="pubmed">34001248</ArticleId></ArticleIdList></Reference><Reference><Citation>Saengsiwaritt W., Jittikoon J., Chaikledkaew U., Udomsinprasert W. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis. Rev. Med. Virol. 2022;8:e2323. doi: 10.1002/rmv.2323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2323</ArticleId><ArticleId IdType="pubmed">34997794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X., Chen K., Zou J., Han P., Hao J., Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020;14:185&#x2013;192. doi: 10.1007/s11684-020-0754-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-020-0754-0</ArticleId><ArticleId IdType="pmc">PMC7088738</ArticleId><ArticleId IdType="pubmed">32170560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Ji P., Pang J., Zhong Z., Li H., He C., Zhang J., Zhao C. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J. Med. Virol. 2020;92:1902&#x2013;1914. doi: 10.1002/jmv.25884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25884</ArticleId><ArticleId IdType="pmc">PMC7262119</ArticleId><ArticleId IdType="pubmed">32293716</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C. Long COVID: Current definition. Infection. 2022;50:285&#x2013;286. doi: 10.1007/s15010-021-01696-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01696-5</ArticleId><ArticleId IdType="pmc">PMC8438555</ArticleId><ArticleId IdType="pubmed">34519974</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Florencio L.L., Cuadrado M.L., Plaza-Manzano G., Navarro-Santana M. Prevalence of Post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur. J. Int. Med. 2021;2021:55&#x2013;70. doi: 10.1016/j.ejim.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review. J. Infect. Dis. 2022;16:jiac136. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M.W., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Di Vincenzo J.D., Cao B., et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal F.M., Lam K., Sounderajah V., Clarke J.M., Ashrafian H., Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. EClinicalMedicine. 2021;36:100899. doi: 10.1016/j.eclinm.2021.100899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100899</ArticleId><ArticleId IdType="pmc">PMC8141371</ArticleId><ArticleId IdType="pubmed">34036253</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., Mitchell R.E., Niedzwiedz C.L., Yang T.C., Huggins C.F., Kwong A.S.F., Silverwood R.J., Di Gessa G., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 2022;13:3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglietta G., Diodati F., Puntoni M., Lazzarelli S., Marcomini B., Patrizi L., Caminiti C. Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022;11:1541. doi: 10.3390/jcm11061541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11061541</ArticleId><ArticleId IdType="pmc">PMC8948827</ArticleId><ArticleId IdType="pubmed">35329867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J., Raizada M.K., Grant M.B., Oudit G.Y. Angiotensin-Converting Enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ. Res. 2020;126:1456&#x2013;1474. doi: 10.1161/CIRCRESAHA.120.317015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317015</ArticleId><ArticleId IdType="pmc">PMC7188049</ArticleId><ArticleId IdType="pubmed">32264791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W., Yang X., Yang D., Bao J., Li R., Xiao Y., Hou C., Wang H., Liu J., Yang D., et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care. 2020;24:422. doi: 10.1186/s13054-020-03120-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03120-0</ArticleId><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D., Chalon P., Kohn L., Dauvrin M., Detollenaere J., Maertens de Noordhout C., Primus-de Jong C., Cleemput I., Van den Heede K. Pathophysiology and Mechanism of Long COVID: A Comprehensive Review. Ann. Med. 2022;54:1473&#x2013;1487. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S.K., Juno J.A., Lee W.S., Wragg K.M., Hogarth P.M., Kent S.J., Burrell L.M. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: Implications for COVID-19 pathogenesis and consequences. Eur. Respir. J. 2021;57:2003730. doi: 10.1183/13993003.03730-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03730-2020</ArticleId><ArticleId IdType="pmc">PMC7830336</ArticleId><ArticleId IdType="pubmed">33479113</ArticleId></ArticleIdList></Reference><Reference><Citation>The PHOSP-COVID Collaborative Group Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: A prospective observational study. Lancet Respir. Med. 2022;10:761&#x2013;775. doi: 10.1016/S2213-2600(22)00127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Giordano R., D&#xed;az-Gil G., Gil-Crujera A., G&#xf3;mez-S&#xe1;nchez S.M., Ambite-Quesada S., Arendt-Nielsen L. Are pain polymorphisms associated with the risk and phenotype of post-COVID pain in previously hospitalized COVID-19 survivors? Genes. 2022;13:1336. doi: 10.3390/genes13081336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13081336</ArticleId><ArticleId IdType="pmc">PMC9394327</ArticleId><ArticleId IdType="pubmed">35893072</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipeto D., Palmeira J.D.F., Arga&#xf1;araz G.A., Arga&#xf1;araz E.R. ACE2/ADAM17/TMPRSS2 interplay may be the main risk factor for COVID-19. Front. Immunol. 2020;11:576745. doi: 10.3389/fimmu.2020.576745.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.576745</ArticleId><ArticleId IdType="pmc">PMC7575774</ArticleId><ArticleId IdType="pubmed">33117379</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti M.K., Al-Sarraj Y.A., Albagha O., Yassine H.M. Host genetic variants potentially associated with SARS-CoV-2: A multi-population analysis. Front. Genet. 2020;11:578523. doi: 10.3389/fgene.2020.578523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.578523</ArticleId><ArticleId IdType="pmc">PMC7567011</ArticleId><ArticleId IdType="pubmed">33133166</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D., Ballouz T., Anagnostopoulos A., Aschmann H.E., Domenghino A., Fehr J.S., Puhan M.A. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS ONE. 2021;16:e0254523. doi: 10.1371/journal.pone.0254523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Mart&#xed;n-Guerrero J.D., Cancela-Cilleruelo I., Moro-L&#xf3;pez-Menchero P., Pellicer-Valero O.J. Exploring the recovery curve for long-term post-COVID dyspnea and fatigue. Eur. J. Intern. Med. 2022;101:120&#x2013;123. doi: 10.1016/j.ejim.2022.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2022.03.036</ArticleId><ArticleId IdType="pmc">PMC9046058</ArticleId><ArticleId IdType="pubmed">35490087</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay A. A paradigm for post-COVID-19 fatigue syndrome analogous to ME/CFS. Front. Neurol. 2021;12:701419. doi: 10.3389/fneur.2021.701419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.701419</ArticleId><ArticleId IdType="pmc">PMC8365156</ArticleId><ArticleId IdType="pubmed">34408721</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M., Freitag H., Rudolf G., Seifert M., Doehner W., Scherbakov N., Hanitsch L., Wittke K., Bauer S., Konietschke F., et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) J. Transl. Med. 2022;20:138. doi: 10.1186/s12967-022-03346-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03346-2</ArticleId><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey R.K., Srivastava A., Singh P.P., Chaubey G. Genetic association of TMPRSS2 rs2070788 polymorphism with COVID-19 case fatality rate among Indian populations. Infect. Genet. Evol. 2022;98:105206. doi: 10.1016/j.meegid.2022.105206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2022.105206</ArticleId><ArticleId IdType="pmc">PMC8730738</ArticleId><ArticleId IdType="pubmed">34995811</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzikowska U., Ding M., Tan G., Zhakparov D., Peng Y., Wawrzyniak P., Wang M., Li S., Morita H., Altunbulakli C., et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75:2829&#x2013;2845. doi: 10.1111/all.14429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14429</ArticleId><ArticleId IdType="pmc">PMC7300910</ArticleId><ArticleId IdType="pubmed">32496587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamet P., Pausova Z., Attaoua R., Hishmih C., Haloui M., Shin J., Paus T., Abrahamowicz M., Gaudet D., Santucci L., et al. SARS-CoV-2 receptor ACE2 gene is associated with hypertension and severity of COVID 19: Interaction with sex, obesity, and smoking. Am. J. Hypertens. 2021;34:367&#x2013;376. doi: 10.1093/ajh/hpaa223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpaa223</ArticleId><ArticleId IdType="pmc">PMC7799248</ArticleId><ArticleId IdType="pubmed">33386398</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Peligro P.J., Casimiro M., Guerrero J.J., Gellaco M.M.L., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. E Clin. Med. 2022;53:201624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>